Eupraxia Pharmaceuticals (EPRX) Common Equity (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 5 years of Common Equity data on file, last reported at $136.2 million in Q1 2026.

• On a quarterly basis, Common Equity rose 403.78% year-over-year to $136.2 million in Q1 2026; TTM through Mar 2026 was $136.2 million, a 403.78% increase from a year earlier, with the FY2025 full-year figure at $80.4 million, up 140.82% from the prior year.
• Common Equity for Q1 2026 stood at $136.2 million, up from $80.4 million in the prior quarter.
• Over the last five years, Common Equity for EPRX reached as high as $136.2 million in Q1 2026 and fell as low as $892326.0 in Q4 2023.
• Historically, Common Equity has averaged $39.5 million across 5 years, with a median of $21.0 million in 2025.
• Across the five-year window, Common Equity slumped 87.62% in 2023 and surged 3643.56% in 2024, its largest moves.
• Year by year, Common Equity stood at $7.2 million in 2022, then slumped by 87.62% to $892326.0 in 2023, then jumped by 3643.56% to $33.4 million in 2024, then surged by 140.82% to $80.4 million in 2025, then soared by 69.29% to $136.2 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $136.2 million in Q1 2026, $80.4 million in Q4 2025, and $88.4 million in Q3 2025.